Trials / Completed
CompletedNCT03697187
Patient Registry to Evaluate the Real-world Safety of Ruconest®
An Observational Patient Registry to Evaluate the Real-world Safety of Ruconest® (C1 Esterase Inhibitor [Recombinant]) for the Treatment of Hereditary Angioedema
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 152 (actual)
- Sponsor
- Pharming Technologies B.V. · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, real-world, observational patient registry for patients with HAE who are receiving treatment with Ruconest for HAE.
Detailed description
See below.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhC1INH | Recombinant human C1 inhibitor |
Timeline
- Start date
- 2018-06-30
- Primary completion
- 2021-06-30
- Completion
- 2021-07-31
- First posted
- 2018-10-05
- Last updated
- 2024-04-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03697187. Inclusion in this directory is not an endorsement.